Skip to main content

Advertisement

SpringerLink
Log in

Estrogen Replacement Therapy and Breast Cancer: Analysis of Age of Onset and Tumor Characteristics

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The use of exogenous estrogen has been scrutinized as a risk factor for breast cancer formation. This prospective study addresses the relationship between the use of estrogen replacement therapy and the age of onset of breast cancer. In addition, an analysis of differences in pathological features of breast cancer between estrogen users and non-estrogen-users was evaluated.

Methods: A total of 425 women (age, ≥ 50 years) were evaluated during a 4-year period (1994–1997). Data, including the age at diagnosis, method of detection, family history, use of estrogen therapy, and tumor ploidy, S-phase fraction, histological category, estrogen receptor positivity, and grade, were prospectively collected. Data from a control group of 657 women without a diagnosis of breast cancer were obtained from the Evanston Northwestern division of the Women’s Health Initiative. Significant associations between the use of estrogen and pathological parameters were determined using the χ2 test and t-test (P < .05).

Results: At the time of breast cancer diagnosis, 140 patients were currently receiving estrogen and 202 patients had no history of estrogen use. Eighty-three patients were excluded from analysis (76 patients had a history of previous but not current use of estrogen therapy, four women used only progesterone, and three patients provided incomplete information). There was no difference between patients with breast cancer using estrogen at the time of diagnosis and those with no history of estrogen use with respect to tumor size, age of menopause, family history, mammographic sensitivity, axillary lymph node status, and histological features. Women using estrogen at the time of diagnosis were younger at the time of breast cancer diagnosis, by an average of 5.1 years (61.3 years vs. 66.4 years, P < .001). Women without a history of breast cancer who were receiving estrogen therapy were an average of 2.4 years younger (63.3 years vs. 65.7 years, P < .001) than women without a history of breast cancer who were not receiving estrogen therapy. Patients with breast cancer receiving estrogen also tended to have more grade II tumors (45.9% vs. 36.5%, P = .045) and fewer grade III tumors (25.6% vs. 37.0%, P =.015), compared with women not receiving estrogen therapy at the time of their diagnoses. Estrogen receptor positivity was noted to be more frequent for estrogen users presenting with lobular carcinoma (85% vs. 76%, P =.042) and less frequent for estrogen users presenting with ductal carcinoma (72% vs. 85%, P = .003).

Conclusions: A significantly earlier age of diagnosis for women receiving estrogen therapy suggests that exogenous estrogen may accelerate the pathogenesis of postmenopausal breast cancer. Estrogen therapy may also play a role in altering the grade and estrogen receptor positivity for certain histological types of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5–27.

    CAS  PubMed  Google Scholar 

  2. Bilimoria MB, Morrow M. Women at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995;45:263–78.

    PubMed  CAS  Google Scholar 

  3. Morrow M, Jordan VJ. Risk factors and the prevention of breast cancer with tamoxifen. Cancer Surv 1993;18:211–29.

    PubMed  CAS  Google Scholar 

  4. Ross RK, Paginini-Hill A, Gerkins, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980;243:1635–9.

    PubMed  CAS  Google Scholar 

  5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59.

    Google Scholar 

  6. Elston CW. The assessment of histological differentiation in breast cancer. Aust N Z J Surg 1984;55:11–5.

    Google Scholar 

  7. Merkel DE, Winchester DJ, Goldschmidt RA, et al. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast Cancer. Cancer 1993;72:1926–32.

    PubMed  CAS  Google Scholar 

  8. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605–13.

    PubMed  CAS  Google Scholar 

  9. Mohle-Boetani JC, Grosser S, Whittemore AS, et al. Body size, reproductive factors, and breast cancer survival. Prev Med 1988;17:634–42.

    PubMed  CAS  Google Scholar 

  10. Lees AW, Jenkins JH, May CL, et al. Risk factors and 10-year breast cancer survival in Northern Alberta. Br Cancer Res Treat 1989;13:143–51.

    CAS  Google Scholar 

  11. Key TJA, Pike MC. The dose-effect relationship between unopposed oestrogens and endometrial mitotic rate: its central role in predicting endometrial cancer risk. Br J Cancer 1988;57:205–12.

    PubMed  CAS  Google Scholar 

  12. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988;148:213–4.

    PubMed  CAS  Google Scholar 

  13. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67–72.

    PubMed  CAS  Google Scholar 

  14. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137–42.

    PubMed  CAS  Google Scholar 

  15. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–90.

    PubMed  CAS  Google Scholar 

  16. Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286–94.

    PubMed  CAS  Google Scholar 

  17. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473–80.

    PubMed  CAS  Google Scholar 

  18. Steinberg KK, Smith SJ, Thacker SB, et al. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5:415–21.

    Article  PubMed  CAS  Google Scholar 

  19. Dupont WD. Estrogen replacement therapy and risk of breast cancer. JAMA 1991;265:1824.

    Google Scholar 

  20. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325–34.

    PubMed  CAS  Google Scholar 

  21. Brinton LA, Hoover R, Fraumeni JF. Menopausal estrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825–32.

    PubMed  CAS  Google Scholar 

  22. Van Gils CH, Otten JDM, Verbeek ALM, et al. Breast parenchymal patterns and their changes with age. Br J Radiol 1995;68:1133–5.

    Article  PubMed  CAS  Google Scholar 

  23. Kaufman Z, Garstin WIH, Hayes R, et al. The mammographic parenchymal patterns of women on hormone replacement therapy. Clin Radiol 1991;43:389–92.

    PubMed  CAS  Google Scholar 

  24. Berkowitz JE, Gatewood OMB, Goldblum LE, et al. Hormone replacement therapy: mammographic manifestations. Radiology 1990;174:199–201.

    PubMed  CAS  Google Scholar 

  25. Stomper PC, Van Voorhid BJ, Ravnikar VA, et al. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487–90.

    PubMed  CAS  Google Scholar 

  26. Cyrlak D, Wong CH. Mammographic changes in postmenopausal women undergoing hormone replacement therapy. Am J Radiol 1993;161:1177–83.

    CAS  Google Scholar 

  27. Doyle GJ, McLean L. Unilateral increase in mammographic density with hormone replacement therapy. Clin Radiol 1994;49:50–1.

    PubMed  CAS  Google Scholar 

  28. Litherland JC, Evans AJ, Wilson AM. The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme. Clin Radiol 1997;52:276–9.

    PubMed  CAS  Google Scholar 

  29. Tavani A, Braga C, La Vecchia C, Negri E, Franceschi S. Hormone replacement treatment and breast cancer risk: an age-specific analysis. Cancer Epidemiol Biomarkers Prev 1997;6:11–4.

    PubMed  CAS  Google Scholar 

  30. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. I. Lancet 1992;339:1–15.

    Google Scholar 

  31. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. II. Lancet 1992;339:71–85.

    Google Scholar 

  32. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women’s Health Study: how many different kinds of breast cancer are there? Cancer Epidemiol Rev 1993;4:319–26.

    Google Scholar 

  33. Allegra JC, Lippman ME, Thompson EB, et al. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 1979;39:1447–54.

    PubMed  CAS  Google Scholar 

  34. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584–9.

    PubMed  CAS  Google Scholar 

  35. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: five-year observations concerning lobular carcinoma in situ. Cancer 1996;78:1403–16.

    PubMed  CAS  Google Scholar 

  36. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11–7.

    PubMed  CAS  Google Scholar 

  37. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control 1994;5:491–500.

    PubMed  CAS  Google Scholar 

  38. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994;178:167–70.

    PubMed  CAS  Google Scholar 

  39. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurse’s Health Study. N Engl J Med 1991;325:756–62.

    Article  PubMed  CAS  Google Scholar 

  40. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease. Cardiovasc Clin 1989;19:159–72.

    PubMed  CAS  Google Scholar 

  41. Kiel DP, Felson DT, Anerson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987;317:1169–74.

    Article  PubMed  CAS  Google Scholar 

  42. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Evanston Northwestern Healthcare, Northwestern University Medical School, 2650 Ridge Road, Evanston, IL, 60201

    Malcolm M. Bilimoria MD, David J. Winchester MD, Stephen F. Sener MD, Gary Motykie MD, Uday L. Sehgal & David P. Winchester MD

  2. Department of Surgery, Evanston Northwestern Healthcare, Northwestern University Medical School, 2650 Ridge Road, Evanston, IL, 60201

    David J. Winchester MD

Authors
  1. Malcolm M. Bilimoria MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Winchester MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen F. Sener MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gary Motykie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uday L. Sehgal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David P. Winchester MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bilimoria, M.M., Winchester, D.J., Sener, S.F. et al. Estrogen Replacement Therapy and Breast Cancer: Analysis of Age of Onset and Tumor Characteristics. Ann Surg Oncol 6, 200–207 (1999). https://doi.org/10.1007/s10434-999-0200-7

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-999-0200-7

Key Words

Search

Navigation